AGEN · Agenus Inc · Financials
$9.93
+0.04 (+0.40%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 7, 2026
Market Cap
$427.47M
Shares
45.02M
Volume · Sep 30
1.37M
Avg daily vol (3M)
4.21M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$114.2M
+10.4%
FY2025
Net Income
-$3.08M
+98.7%
FY2025
Gross Margin
99.11%
-0.4pp
FY2025
Operating Margin
-17.66%
+98.8pp
FY2025
Diluted EPS
$0.00
+100%
FY2025
Operating Cash Flow
-$77.2M
+51.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $132.69M | $114.2M | $103.46M | $156.31M | $98.02M | $295.67M | $88.17M | $150.05M | $36.78M | $42.88M | $22.57M | $24.82M | $6.98M | $3.05M | $15.96M | $2.76M | $3.36M | $3.33M | |
| $642K | $1.02M | $486K | $3.11M | $10.57M | $3.47M | $2.35M | — | — | — | — | — | $0 | $536.12K | $671.97K | $0 | $122.95K | $0 | |
| $132.05M | $113.17M | $102.98M | $153.2M | $87.46M | $292.2M | $85.82M | — | — | — | — | — | $6.98M | $2.51M | $15.29M | $2.76M | $3.24M | $3.33M | |
| — | 99.11% | 99.53% | 98.01% | 89.22% | 98.83% | 97.34% | — | — | — | — | — | 100% | 82.39% | 95.79% | 100% | 96.34% | 100% | |
| $57.69M | $79.34M | $155.53M | $234.57M | $186.69M | $178.61M | $142.62M | $168.34M | $124.6M | $116.13M | $94.97M | $70.44M | $22.35M | $13.01M | $10.56M | $11.02M | $12.88M | $16.9M | |
| $38.48M | $54.39M | $71.88M | $78.74M | $81.01M | $76.36M | $59.22M | $46.04M | $37.34M | $33.74M | $33.13M | $28.37M | $21.25M | $14.48M | $11.47M | $10.82M | $12.11M | $14.11M | |
| — | $300K | $500K | $1.5M | $2.2M | $2.1M | $2.4M | $2M | $2M | $2.3M | $2.2M | $2.2M | $462K | $0 | — | — | $690K | — | |
| $4.73M | $10M | $13.34M | $13.59M | $6.95M | $6.79M | $7.18M | $6.66M | $6.29M | $6.01M | $4.95M | $1.96M | $1.58M | $586.34K | $1.62M | $2.25M | $3.44M | $4.11M | |
| $36.2M | -$20.17M | -$120.48M | -$159.55M | -$179.43M | $25.75M | -$117.24M | -$70.14M | -$123.82M | -$103.8M | -$107.48M | -$80.7M | -$43.32M | -$24.98M | -$6.74M | -$19.09M | -$21.75M | -$27.68M | |
| — | -17.66% | -116.44% | -102.07% | -183.04% | 8.71% | -132.96% | -46.74% | -336.62% | -242.09% | -476.12% | -325.18% | -620.87% | -820.31% | -42.23% | -692.61% | -647.47% | -830.08% | |
| $40.93M | -$10.17M | -$107.13M | -$145.96M | -$172.48M | $32.54M | -$110.06M | -$63.48M | -$117.53M | -$97.8M | -$102.53M | -$78.74M | -$41.74M | -$24.39M | -$5.12M | -$16.83M | -$18.31M | -$23.57M | |
| $59.35M | $55.62M | $120.42M | $103.86M | $64.12M | — | — | — | — | — | — | — | $1.26M | $2.42M | $4.69M | $4.21M | $4.87M | $5.34M | |
| $245K | $345K | $2.8M | $5.93M | $2.26M | — | — | — | — | — | — | — | — | $7931 | $23.34K | $18.79K | $37.56K | — | |
| -$1.3M | -$2.22M | $5.83M | $37K | $12.57M | $5.05M | -$1.86M | $28K | -$2.18M | $1.98M | -$2.2M | -$5.97M | $2.1M | -$2.67M | $110.47K | $1941 | $4.68M | $2.57M | |
| — | -$26.35M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$3.08M | -$232.27M | -$257.44M | — | — | — | — | — | -$120.69M | -$127M | -$93.27M | -$42.49M | -$30.07M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$5.39M | $0 | $0 | $0 | $0 | — | — | |
| $91.94M | -$3.08M | -$232.27M | -$257.44M | -$230.66M | -$28.72M | -$182.89M | -$111.56M | -$162.04M | -$120.69M | -$127M | -$87.88M | -$42.49M | -$30.07M | -$11.32M | -$23.28M | -$21.91M | -$30.32M | |
| — | -2.7% | -224.5% | -164.69% | -235.31% | -9.71% | -207.43% | -74.35% | -440.53% | -281.48% | -562.59% | -354.12% | -608.91% | -987.54% | -70.95% | -844.63% | -652.05% | -909.22% | |
| -$74K | -$3.2M | -$5.06M | -$11.68M | -$10.58M | -$4.8M | -$1.98M | -$3.9M | -$2.35M | — | — | — | — | — | — | — | — | — | |
| $91.8M | -$101K | -$227.43M | -$245.97M | -$220.29M | -$24.14M | -$181.12M | -$107.87M | -$159.9M | -$120.9M | -$127.2M | -$88.08M | -$42.69M | -$33.23M | -$12.12M | -$24.07M | -$22.7M | -$31.11M | |
| -$90.03M | — | — | — | — | — | — | — | — | — | — | -$88.17M | -$44.66M | -$33.23M | -$12.12M | — | — | — | |
| USD/shares | $3.05 | $0.00 | -$10.59 | -$13.75 | -$15.64 | -$2.20 | -$20.61 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $3.04 | $0.00 | -$10.59 | -$13.75 | -$15.64 | -$2.20 | -$20.61 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 29.73M | 21.47M | 17.89M | 14.09M | 11.45K | 8789.0788 | 6877.3329 | 5643.8334 | 5014.2443 | 4.44M | 3.98M | 3.04M | 1.52M | — | — | — | — |
| shares | — | 29.73M | 21.47M | 17.89M | 14.09M | 11.45K | 8789.0788 | 6877.3329 | 5643.8334 | 5014.2443 | 4.44M | 3.98M | 3.04M | 1.52M | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2011: $54.94K in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.31×
Peer median 5.17×
EV/EBIT
12.12×
Peer median 10.09×
P/E (TTM common income)
4.66×
Peer median 11.61×
Peer medians compare against the 321 similar-size Biotechnology companies (of 532 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $113,160,000 | $101,460,000 | $153,336,000 | $87,510,000 | $288,961,000 | $83,551,000 | $149,358,000 | $32,784,000 |
| Non Us | $1,036,000 | $2,003,000 | $2,978,000 | $10,514,000 | $6,704,000 | $4,619,000 | $690,000 | $4,000,000 |
| Rest of World | — | — | — | $10,514,000 | $6,704,000 | $4,619,000 | $690,000 | $4,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non-Cash Revenue Related to Sale of Future Royalties | $108,588,000 | $100,978,000 | $114,572,000 | $45,285,000 | $44,355,000 | $47,545,000 | — | — |
| Non-Cash Royalty Revenue | $108,588,000 | $100,978,000 | $114,572,000 | $45,285,000 | $44,355,000 | — | — | — |
| Pre-Commercial Product Revenue | $4,238,000 | $0 | $0 | — | — | — | — | — |
| Other | $1,036,000 | $2,003,000 | $2,978,000 | $10,514,000 | $6,704,000 | $4,619,000 | — | — |
| Revenue | $1,036,000 | $2,003,000 | $2,978,000 | $10,514,000 | $6,704,000 | $4,619,000 | — | — |
| Clinical Product Revenue | $334,000 | $482,000 | $116,000 | $762,000 | $587,000 | — | — | — |
| Research and Development Revenue | $334,000 | $482,000 | $38,764,000 | $16,975,000 | $244,422,000 | $35,915,000 | $99,845,000 | $19,475,000 |
| Clinical Product Revenue 1 | — | — | — | — | $587,000 | — | — | — |
| License and Collaboration Milestones | — | — | — | — | $220,000,000 | $22,857,000 | $75,500,000 | $14,000,000 |
| License Fee Revenue | — | — | $25,000,000 | $5,000,000 | $220,000,000 | $22,857,000 | — | — |
| Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone | — | — | — | $45,285,000 | $44,355,000 | $47,545,000 | $30,424,000 | $17,309,000 |
| Recognition of Deferred Research and Development Revenue | — | — | $12,213,000 | $9,537,000 | $22,359,000 | $12,304,000 | $22,638,000 | $1,325,000 |
| Research and Development Services | — | — | $1,435,000 | $1,676,000 | $1,476,000 | $754,000 | $1,707,000 | $4,150,000 |
| Royalty Sales Milestone | — | — | — | $25,250,000 | — | — | $15,100,000 | — |
| Grant | — | — | — | — | $184,000 | $91,000 | $1,342,000 | — |
| License | — | — | — | — | — | — | $75,500,000 | — |
| Manufacturing Facility | — | — | — | — | — | — | $3,337,000 | — |
| Product And Service Other | — | — | — | — | $184,000 | $91,000 | $4,679,000 | — |